NEW YORK — After years of living in the shadow of trillion-dollar tech titans, the "little guys" of the stock market are finally having their day in the sun. As of February 24, 2026, the financial landscape has undergone a dramatic shift, punctuated by a stunning 5.4% surge in the
As of February 23, 2026, the biotechnology landscape has shifted away from the speculative fervor of the early 2020s toward a demand for commercial execution and sustainable revenue. Standing at the center of this transformation is Axsome Therapeutics (Nasdaq: AXSM), a mid-cap CNS (Central Nervous System) specialist that has successfully navigated the "valley of death" [...]
In a move that has rewritten the record books of Wall Street, the small-cap-heavy Russell 2000 index recently concluded a historic 15-session winning streak of daily outperformance against the S&P 500. This rally, which reached its zenith on January 22, 2026, represents the longest period of small-cap dominance since
As the final bells rang on the 2025 trading year, investors in Regencell Bioscience (NASDAQ: RGC) were met with a sobering reality check. The Hong Kong-based biotech firm, which has enjoyed a meteoric and often volatile rise over the past twelve months, saw its stock slide 8.3% on December
